Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma (Q35670248)

9 August 2017

Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma (English)

1 reference

9 August 2017

phase II clinical trial

0 references

1 reference

Ana M Molina

1

1 reference

9 August 2017

Darren R Feldman

2

1 reference

9 August 2017

Michelle S Ginsberg

3

1 reference

9 August 2017

Glenn Kroog

4

1 reference

9 August 2017

Satish K Tickoo

5

1 reference

9 August 2017

Xiaoyu Jia

6

1 reference

9 August 2017

Murielle Georges

7

1 reference

9 August 2017

Sujata Patil

8

1 reference

9 August 2017

Michael S Baum

9

1 reference

9 August 2017

Victor E Reuter

10

1 reference

9 August 2017

Robert J Motzer

11

1 reference

9 August 2017

14 August 2010

1 reference

Investigational New Drugs

9 August 2017

1 reference

9 August 2017

30

1 reference

9 August 2017

1

1 reference

9 August 2017

335-340

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-010-9491-6

9 August 2017

0 references

cites work

Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257373

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257373

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257373

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257373

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257373

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257373

Sorafenib in advanced clear-cell renal-cell carcinoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257373

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257373

Sunitinib in patients with metastatic renal cell carcinoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257373

Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257373

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257373

Contemporary approach to the classification of renal epithelial tumors.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257373

Systemic therapy for renal cell carcinoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257373

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257373

Adult renal epithelial neoplasms

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257373

Optimal two-stage designs for phase II clinical trials

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257373

A comparative study of metastatic renal cell carcinoma with correlation to subtype and primary tumor.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257373

Nonparametric Estimation from Incomplete Observations

25 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-010-9491-6

Specific chromosome aberration in human renal cell carcinoma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20711632

12 December 2020

inferred from PubMed ID database lookup

The impact of genetics on the classification of renal carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20711632

12 December 2020

inferred from PubMed ID database lookup

Cytogenetic analysis of epithelial renal-cell tumors: relationship with a new histopathological classification

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20711632

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S10637-010-9491-6

1 reference

release_uxlxvtjxzrczzlzzhutr4om55y

9 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/uxlxvtjxzrczzlzzhutr4om55y

24 November 2022

mapped directly with Wikidata item

PMCID

3257373

1 reference

9 August 2017

1 reference